Showing results (101-110 of 119) with videos related to
Sort By:
Pageof 12
Cell|August 29, 2015
Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous RetrovirusesKatherine B Chiappinelli, Pamela L Strissel, Alexis Desrichard, et al.Nature Communications|April 12, 2022
Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinomaJeppe Sejerø Holm, Samuel A Funt, Annie Borch, et al.Science (New York, N.Y.)|March 14, 2015
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancerNaiyer A Rizvi, Matthew D Hellmann, Alexandra Snyder, et al.Nature|June 18, 2019
TOX is a critical regulator of tumour-specific T cell differentiationAndrew C Scott, Friederike Dündar, Paul Zumbo, et al.Nature Medicine|August 7, 2015
Toward understanding and exploiting tumor heterogeneityAsh A Alizadeh, Victoria Aranda, Alberto Bardelli, et al.Nature Medicine|July 10, 2023
Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim resultsMartin Gutierrez, Wei-Sen Lam, Matthew D Hellmann, et al.Science (New York, N.Y.)|January 6, 2018
Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinomaDiana Miao, Claire A Margolis, Wenhua Gao, et al.Open Forum Infectious Diseases|April 6, 2026
Serum Biomarkers of Macrophage Activation and Incident CKD in People With and Without HIV: Findings From the MACS-WIHS Combined Cohort StudyMolly C Fisher, David B Hanna, Donald R Hoover, et al.Journal of the American Society of Nephrology : JASN|October 15, 2011
APOL1 variants increase risk for FSGS and HIVAN but not IgA nephropathyNatalia Papeta, Krzysztof Kiryluk, Ami Patel, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 17, 2018
Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation SequencingHira Rizvi, Francisco Sanchez-Vega, Konnor La, et al.Pageof 12